Alacrity Biosciences Inc.

Alacrity's strategy is to in-license products that have particular promise in key ophthalmic indications, such as dry eye, glaucoma, and retinal disease. According to its founders, its specialty is recognizing the potential of these products, licensing them in, and taking them through the development process--formulation, preclinical toxicology, clinical development--everything that's needed to take a drug to the FDA and other regulatory agencies.